Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Compounding/Track And Trace Bill Another Victim Of Shutdown

This article was originally published in The Pink Sheet Daily

Executive Summary

The stripped down version will generate considerably less user fee revenue for FDA, but so far it has met the same fate in the Senate as other recent legislation coming from the House.

You may also be interested in...



FDA’s Shutdown Plan: Some User Fee Services Would Continue; Routine Inspections Would Not

The agency would retain 8,180 staff members, about 55% of its total, mostly because they could be “paid from carryover funding.”

Compounding Bill In Senate Gets Bipartisan Push For Floor Vote

HELP Committee leaders Harkin and Alexander write letter arguing that FDA’s warnings of more problems from tainted compounded medications have come true and that their legislation should gain a vote next month.

Generic Drugs: ‘Competitive’ Exclusivity Benefited Few Sponsors But Is Increasingly Popular

The six months of additional exclusivity from US FDA’s CGT program appears to have kept some generic sponsors from the market, and didn’t even prompt others to enter quickly, but use of the competitive generic exclusivity program continues to grow.

Topics

UsernamePublicRestriction

Register

PS074990

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel